clarithromycin has been researched along with fleroxacin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bale, MJ; Erwin, ME; Gerlach, EH; Jones, RN; Koontz, FP; Murray, PR; Washington, JA | 1 |
| Muszynski, MJ; Rajyaguru, JM | 1 |
| Ansorg, R; Fabry, W; Schmid, EN | 1 |
7 other study(ies) available for clarithromycin and fleroxacin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.
Topics: Anti-Bacterial Agents; Cefdinir; Cefpirome; Ceftibuten; Ceftizoxime; Cephalosporins; Clarithromycin; Erythromycin; Fleroxacin; Fluoroquinolones; Haemophilus; Humans; Microbial Sensitivity Tests; Quality Control; Quinolones; Spectinomycin; Virginiamycin | 1992 |
Enhancement of Burkholderia cepacia antimicrobial susceptibility by cationic compounds.
Topics: 1-Naphthylamine; Anti-Infective Agents; Azithromycin; Bacterial Outer Membrane Proteins; Burkholderia cepacia; Cations; Ceftazidime; Cell Membrane Permeability; Ciprofloxacin; Clarithromycin; Fleroxacin; Fluorescent Dyes; Fluoroquinolones; Gentamicins; Magnesium; Microbial Sensitivity Tests; Microscopy, Electron; Novobiocin; Oxolinic Acid; Polysaccharides, Bacterial; Tobramycin | 1997 |
Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium tuberculosis.
Topics: Amikacin; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Fleroxacin; Fusidic Acid; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Streptomycin | 1995 |